Savara is covered by roughly eight to nine sell-side analysts, and the targets reviewed cluster between $9 and $16. On the cautious end, Wells Fargo carries a $9 target, while Piper Sandler's Yasmeen Rahimi holds the Street-high $16 target. In between, H.C. Wainwright is at $10, Jefferies' Andrew Tsai at $10.50, Guggenheim at $11, and both JPMorgan and Citigroup initiated coverage in October 2026 with $12 targets. The arithmetic mean of these verified targets lands near $11.06–$11.17, which rounds to the $11 central target used here.
The dispersion is meaningful. Lower targets reflect a conservative view of launch execution and peak-sales penetration, while the $16 target assumes a faster, larger commercial ramp and greater ex-U.S. upside. Crucially, the mean is a statistical midpoint, not a promise, and the gap between $9 and $16 underscores how much of the valuation debate hinges on one binary event: FDA approval.
Shares traded near $4.99 in mid-November 2026, within a 52-week range that has stretched from roughly $4 to above $7. Reaching $11 would require a gain of about 120%, which qualifies as a very large move for any established company and is especially demanding for a pre-revenue biotech.
The path runs directly through the November 22, 2026 PDUFA (Prescription Drug User Fee Act) decision date for MOLBREEVI. Savara's BLA (Biologics License Application) was accepted under Priority Review, and the FDA extended the original August 2026 date by three months without citing safety, efficacy, or manufacturing concerns. A positive decision would shift the market's focus from regulatory risk to commercial launch, potentially re-rating the stock toward the higher end of the target range. A negative or delayed outcome could pressure shares sharply in the opposite direction.
The stock has been volatile around the regulatory catalyst. It recently recovered from the low-$4.20s in late October 2026 to the mid-$4.80s, but remains well below its 52-week high near $7. That prior high zone acts as meaningful overhead resistance on any path toward double digits, while the $4 area has functioned as durable support. The $11 target sits far above both the recent trading range and the prior peak, meaning the stock would need to break out decisively to make a technical case for that level.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms vary. For Savara, the near-term calendar is unusually event-driven. The November 22, 2026 PDUFA decision is the dominant catalyst, followed by EMA and MHRA decisions expected in Q1 2027 and Q4 2026, respectively. Investors should also watch quarterly cash burn, any capital-raising announcements, launch preparation updates, and analyst target revisions after the FDA ruling.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a binary-event stock like Savara, tools that flag shifting momentum and trend changes can help traders track positioning without manually sifting through charts. Traders can use these signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently.
The $11 central target is the arithmetic mean of verified analyst targets spanning $9 to $16, and it sits roughly 120% above the current price—a very large, catalyst-dependent move. The case for reaching it rests almost entirely on a favorable FDA decision and a credible commercial launch, supported by a solid cash position and genuine unmet medical need. The case against it rests on binary regulatory risk, continued losses, dilution, and the possibility that launch economics disappoint even if approval arrives. Given the wide analyst range and the concentrated event risk around November 22, 2026, the $11 figure is best understood as a midpoint of sharply diverging views rather than a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with FDMT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To SVRA | 1D Price Change % | ||
|---|---|---|---|---|
| SVRA | 100% | +1.42% | ||
| FDMT - SVRA | 51% Loosely correlated | +4.25% | ||
| MGTX - SVRA | 47% Loosely correlated | +0.62% | ||
| ANNX - SVRA | 46% Loosely correlated | -0.48% | ||
| KYTX - SVRA | 45% Loosely correlated | +0.79% | ||
| KURA - SVRA | 45% Loosely correlated | +2.11% | ||
More | ||||